Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Researchers have found a potential game-changing way to help people lose weight and control blood sugar without the ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...